Table 1.
Genes comprising the Slug-based EMT signature.
Figure 1.
Scatter plot for Days to Tumor Recurrence vs. expression of the mesenchymal transition metagene.
Each dot in the scatter plot represents one of the 99 patients for which the “Days to Tumor Recurrence” phenotype has a non-null entry. The horizontal axis measures the average of the RMA-normalized expression levels of the 64 genes shown in Table 1. The vertical axis measures the days to tumor recurrence and the horizontal dotted line is drawn at the 3 year cutoff point.
Figure 2.
Heat map of the components of the mesenchymal transition metagene in glioblastoma.
The 99 samples are ranked in terms of the average expression level of the genes shown in Table 1. The eight patients for which time to recurrence was more than three years are highlighted in green at the 1st, 2nd, 6th, 7th, 9th, 11th, 16th, and 18th position, resulting in the rank sum of 70.
Figure 3.
Kaplan-Meier curves comparing samples with high vs. low levels of the mesenchymal transition metagene.
The 545 tumor samples were partitioned into two groups of equal size depending on their levels of the mesenchymal transition metagene. Shown are the Kaplan-Meier curves for the corresponding samples with entries in the “Days to Tumor Recurrence” field.
Table 2.
Top genes in terms of the rank sum for the “Days to Tumor Recurrence” phenotype.
Figure 4.
Scatter plot for the expression levels of CD44 vs. the mesenchymal transition metagene.
Each dot in the scatter plot represents a glioma sample from the NCI Repository for Molecular Brain Neoplasia Data (Rembrandt) dataset. Dots are color coded red for glioblastomas and blue for lower grade gliomas. Expression levels are RNA normalized.
Table 3.
Top differentially expressed gene in glioblastomas vs. lower grade gliomas.
Table 4.
Multivariate Cox regression using GBM subtypes as covariates.